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INTRODUCTION 
 
Neuroblastoma is one of the commonest solid tumor in the 
paediatric age group with an overall poor prognosis. Stage 4S 
Neuroblastomas as the S stands for is a special group among 
neuroblastomas. Interesting to note that age is a major criteria 
which differentiates between two groups of patients at either end of 
the prognostic spectrum.The neuroblastomas presenting after  1yr 
with all other features of 4 S seem to behave so,different from the 
actual 4S Neuroblastomas. These 4S NBs have many unique 
characteristics. Most important of them being tumor regression and 
tumor maturation. 
 
Another interesting fact about these tumors is that it defies 
the conventional definition of metastatic disease.Because in 4 S 
NB’s despite their widespread metastasis prognosis is considered 
as good and the chances that such tumors will regress is very 
good. 
 
There have also been disputing claims that these are 
incidentalomas and cannot be classified as tumors However there 
are enough studies to prove that these are true tumors very similar 
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to their non 4 S counterparts and are capable of metastazing and 
even sometimes progressing rapidly ,with poor outcome. 
 
Though most of these tumors regress and disappear some 
progress on to stage 4 with resultant poor prognosis.There are few 
pointers to predict tumor progression and regression.This 
phenomenon is much less studied and understood.This study aims 
to evaluate the natural course of the disease and to identify the 
changing patterns of disease regression and maturation. 
 
The present scenario of unpredictable disease pattern and 
behavior gives rise to the  question of whether to treat these 
individuals or not. Chemotherapy  with its attendant complications 
in this age group is very risky.On the other hand, to wait and watch 
a tumor which has metastasized is a difficult decision.There have 
been various studies supporting and opposing chemotherapy in 4 
S Neuroblastomas in the literature.This  study aims to formulate a 
protocol  for identifying between the cases to be treated from those 
which need to be just observed and followed up.In our setup,where 
molecular studies and genetic markers are not easily available,we 
aim to formulate a simplified selection criteria,based on the 
available resources to identify the patients requiring chemotherapy. 
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REVIEW OF LITERATURE 
 
Neuroblastomas is the most common malignant tumor of 
neonates and the second most common solid tumor in children.The 
prevalence is 1 per 7000 live births,overall with slightly lesser 
prevalence in whites. 
 
It has a slight male preponderance with a male to female 
ratio of 1:2:1The median age at diagnosis is around 22months. 
36% of the patients are less than 1 year at diagnosis. Studies show 
a biphasic age incidence with an initial peak before 1 year and a 
second peak between 2 and 4 years. 
 
Environmental Influence  
 
Studies show an association between maternal exposure to 
drugs like diuretics and neurally active drugs, like Phenobarbital 
and phenytoin.Two other studies have shown association between 
paternal exposure to electromagnetic fields and 
neuroblastomas.These studies however have not been confirmed. 
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Genetic predisposition: 
A subset of patients with neuroblastoma exhibit an 
Autosomal dominant form of inheritance. Knudson and Strong 
postulate that 22% of all neuroblastomas are due to a germinal 
mutation.According to Knudsons hypothesistwo serial mutations 
occurring in a single cell induces malignant transformation in the 
cell. Hereditary tumors occur in patients in whom the first mutation 
is a prezygotic ( germinal ) event. Only one additional mutation is 
needed in these persons to induce malignant transformation. Such 
persons have a higher incidence of neuroblastoma and a peak 
incidence at an early age. In addition,they may develop tumors at 
multiple sites and bilateral tumors. 
 
The median age at diagnosis of familial neuroblastomas is 9 
months in contrast to the 22 months in general population.If such 
persons survive, half of their  offsprings should be carriers of the 
geminal mutation with atleast a 63 % chance of developing 
neuroblastoma.The concordance for neurobastoma in monozygotic 
siblings during infancy suggests that hereditary factors may be 
predominant ,whereas the discordance in older twins suggests that 
random mutations or other factors may play a role. 
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Chromosomal Abnormalities: 
Reports describe constitutional abnormalities involving the 
short arm of chromosome 1 ,which is frequently deleted or 
rearranged in neuroblastoma cells.The break point is at 1p 36.This 
break point may interrupt a gene on 1p 36that is important in 
malignant transformation. 
 
Associated Genetic Syndromes: 
Neuroblastoma is associated with neurofibromatosis type I 
and aganglionosis of the colon. All these are neurocristinopathies 
which may represent a maldevelopment of the neural crest. 
 
Cellular and Molecular Pathogenesis : 
Studies at cellular and Molecular level in  neuroblastoma 
have led to better means of diagnostic subclassification. 
Besides,they also provide better means of understanding and 
predicting the clinical behavior and following up the disease activity 
in these patients. In addition to providing insights into mechanisms 
of malignant transformation and progression ,these studies 
promise to generate novel approaches to treatment. 
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Embryology : 
Studies show crests of neuroblastoma cells occur within the 
fetal adrenal that may be identified in neonates and infants.These 
nodules occur as part of normal Adrenal development, peak 
between 17 and 20  weeks of gestation and gradually regress by 
birth or shortly thereafter. 
 
Thus , the neuroblastic nodules identified in 3 month old 
infants who died of other causes were likely remanants of fetal 
adrenal development. 
 
However,it has been proven beyond doubt that cells in these 
crest are the ones from which adrenal neuroblastomas 
develop.The factors that induce the changes which predispose to 
development of Neuroblastoma from these cells are not completely 
understood. 
 
These microscopic nodules however are unlikely to be 
detected clinically or by screening for the urine VMA ,as done in 
mass screening programmes. 
 
The concept of “in situ “ neuroblastomas and the 
“spontaneous regression“ of 4 S Neuroblastomas have been 
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variously argued to represent an extension of this normal 
phenomenon of adrenal crest development and regression. 
Though the ‘ in situ ‘ neuroblastoma can be explained so ,the 4 
SNB do not fit into this category and represent an exclusive group 
themselves. 
 
Neuroblastoma cells are derived from postganglionic 
sympathetic neuroblasts. They sometimes exhibit features of 
neuronal differentiation. Indeed,neuroblastomas may show 
spontaneous or induced differentiation to ganglioneuroblastoma or 
ganglioneuroma. Thus malignant transformation of these cells may 
result in part from failure to respond fully to normal signals to 
undergo morphologic differentiation. 
 
Markers of neuronal differentiation have been identified 
which when present indicate that the tumors are likely to be more 
differentiated .The nerve growth factor (NGF) is a member of a 
family of neurotropins which include brain derived neurotroptic 
factors, neurotropin 3,4,5. Tyrosine kinase receptor genes (Trk 
A,B,C) have been cloned which encode for the receptors for these 
neurotropins. Of these, Trk A gene is most commonly observed in 
neuroblastoma. Presence of Trk A gene is associated with tumors 
which are likely to differentiate and thus represent a favourable 
prognosis. 
 8
 
Two other markers of neuronal differentiation have been 
identified –Chromogranin  A and Neuropeptide Y.apart from these 
somatostatin and VIP are peptide hormones which are associated 
with good prognosis in neuroblastomas and might serve as indirect 
evidence of differentiated tumors. 
 
Tumor Karyotyping : 
 Tumor cells may show 1 p36 deleton on karyotyping .This  
however carries no importance as far as the disease progression 
or treatment plan is concerned. 
 
DNA Index: 
 Flow cytometric analysis of DNA content gives useful 
information on prognosis and response to chemotherapy .Diploid 
tumors have a DI of 1 and are associated with poor prognosis 
.Hyperdiploid tumors with a DI of > 1 are likely to have a better 
prognosis especially in the infancy age group. 
 
N-myc Amplification: 
Gene amplification of specific areas especially the short arm 
of chromosome 2 which contains the N-myc protooncogene is 
associated with advanced disease ,whereas the reverse is true for 
stage 1,2 and 4S disease. Also N-myc is present at time of 
presentation and does not change with the progresson of disease. 
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1p36 deletion: 
 This is found in 70 to 80% of Diploid tumors. Molecular 
studies indicate a strong correlation between 1p36 deletion and N-
myc Amplification. 
 
Pathology of  Neuroblastomas 
It is one of the “small blue round cell “,neoplasms which 
includes Ewings,NHL,PNET and RMS. Neuroblastomas arise from 
primitive pluripotent sympathetic cells which are derived from the 
neural crest.The pleuripotent sympathogonia which are derived 
from the neural crest migrate and undergo varing degree and type 
of differentiation to generate different normal tissues of the 
sympathetic nervous system including the Adrenal chromoffin cells 
and the spinal sympathetic ganglia. 
 
The histological subtypes of neuroblastic tumors appear to 
correlate with the normal differentiation patterns of the sympathetic 
nervous system. 
 
The three recognized classical patterns of Neuroblastoma, 
Ganglioneuroblastoma and Ganglioneuroma reflect a spectrum of 
maturation and differentiation. 
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The neuroblastoma is composed of small, uniform cells 
containing dense hyperchromatic nuclei and scant ctytoplasm.The 
presence of neuritic processes or neurophil is pathognomonic. The 
Holmer Wright pseudorosette is another diagnostic feature of 
neuroblastoma seen in 15 to 50 % cases.It is composed of 
neuroblasts surrounding the eosinophilic neurophil. 
 
At the other end of the spectrum the ganglioneuroma is 
composed of mainly ganglion cells,neurophil and schwann cells. 
Ganglioneuroblastomas are a heterogenous group with 
histopathological features spanning between the 
two.Ganglioneuroblastoma may be either focal or diffuse with the 
diffuse ones being less aggressive.  
 
Once a diagnosis of small round cell tumor is made,there 
may still be some doubt in confirming the diagnosis when the 
classical pseudorosette or neurophil are not identified. 
 
At this point immunohistochemsitry and electron microscopy 
help. Neuroblatoma is positive for neurofilaments synaptophysin 
and neuronspecific enolase,by immunohstochemistry.Electron 
microscopy typically demonstrates dense core membrane bound 
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neurosecretory granules as well as microfilaments and microtibules 
within the neurophil. 
Definition of 4 S Neuroblastoma.: 
It is defined as stage I or II disease with spread limited to the 
liver,skin, bone marrow ( less than 10 % involvement), in a  child 
under 12 months of age.Bone cortex is not involved. The ‘’S” in 4S 
neuroblastomas represents ”special “These represent a unique 
subgroup within the neuroblastomas which show spontaneous 
regression without any treatment. 
 
Diagnostic Criteria : 
1.Stage I or II disease proven by histopathology ,ie, Tissue 
from primary or Bone marrow + Urine VMA studies. 
2. Absence of disease elsewhere apart from liver ,skin and  
bone marrow.This has to be confirmed by an USG / CT Scan 
abdomen /Xray chest / skeletal  survey. 
3. Age < 1 year at presentation. 
 In only 1-2% of the patients does the disease progress to 
stage  
The major risk for infants with stage 4 S disease comes from 
systemic effects of the disease ,chief among them being 
respiratory distress caused by a massively enlarged liver.Other risk 
factors being Coagulopathy ,renal failure,vomiting and all caused 
by the enlarged liver. The risk of such systemic effects is much 
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higher in infants <3 months of age. It is for this reason they are 
considered as a high risk group within the 4 S NB group. 
The prognosis of 4 S NB is good with an overall survival of 
85 to 90%. DeBernandi found out that cases presenting < 6 
months of age did better than those between 6 and 12 months of 
age ( 92 % Vs 80 % ). 
 
The commonest mode of presentation is an abdominal 
mass. Adrenal is the MC site of primary 60(%).In 5..% cases, 
however a primary could not be detected .Among the three 
secondary sites (Liver,Skin & BM ),presence of subcutaneous 
nodules indicates a good prognosis .Urine VMA is detectable in 90 
to 95 % of cases. 
 
Prognostic Factors : 
The prognostic factors for 4 S NB is same as that for all 
neurobblastomas. Of all the prognostic factors some carry a 
greater significance. 
 
The Shimada histopathological grading is one based on the 
patients age along with three histopathological factors. 
1. Presence or absence of Stroma. 
2. Degree of differentiation. 
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3. Mitosis –Karyorrhexis index. 
 
Generally  age < 1 year ,stroma rich well differentiated 
tumors,MK Index of  <100 indicate good prognosis. 
 
Joshi et al have proposed three grades based on two factors 
namely presence of calcification and mitotic rate.Less than 10 
mitoses / 10 HPF (indicates low mitotic rate) 
 
Grade I : Calcification present / Low mitotic rate. 
Grade II : either one only present. 
Grade III : Both absent. 
 
Apart from these histological criteria genetic markers like N-
myc amplification,1p36 deleton and DNA index are of great 
prognostic significance. 
 
N-myc is a protooncogene situated in the short arm of 
chromosome 2.This genes when amplified are identified as 
homogeneously straining region within the chromosme. Nmyc 
amplification is associated with predominantly advanced 
stage,rapidly progressing disease and other poor prognostic 
factors. 
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Amplification is found in 5 to 10 % of allpatients with 4 S .But 
m, it is noted in 30 to 40 % of those in the 4 S group which 
progress to stage 4. N-myc is present from the time of diagnosis 
and does not change with the course of the disease.Thus it serves 
as a good predictor of disease behaviour. 
 
Flow cytometry analysis of measures total cell DNA 
content.Diploid tumors have a DI of 1.Hyperdilpoid tumors with DI . 
>1 are likely to have low stage of disease and respond better to 
cyclophosphamide and doxorubicin.Diploid tumors (DI = 1) on the 
other hand are poor responders. 
 
Loss of Heterozygosity for 1 p is another factor associated 
with poor prognosis. 
 
Children’s oncology group  ,North  America has classified 
the neuroblastoma cases based on tumor biology.The three criteria 
being considered are N-myc Amplification, shimada histology and 
DNA ploidy. 
 
Low risk 4 S Neuroblastoma. 
N-myc not amplified. 
Favourable shimada histology. 
Hyperdiploid DNA. 
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Intermediate risk 4 S Neuroblastoma. 
N-myc not amplified. 
Unfavourable shimada histology 
And / or 
Diploid DNA 
 
High risk 4 S Neuroblasstoma : 
N-myc amplified. 
 
Apart from these few other variables also serve as markers of 
prognosis. 
• Age >6 months at presentation, likelihood of progressing 
into stage 4 disease. 
• Elevated Serum ferritin is associated with poor prognosis 
because they may indicate an increased tumor load.On 
the other hand ferritin may be needed for growth of NB 
cells. 
• Neuron specific enolase activity is directly proportional to 
the neural cells.Elevated levels indicate rapidly 
progressing Active tumor.However NSE is not specific 
for neuroblastomas and may be elevated in other tumors 
also. 
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• GD2 is the most characteristic ganglioside on 
neuroblastoma cells.It can be also detected in the serum 
and useful as a marker of disease activity and response 
to treatment. 
• Increased Serum LDH levels may reflect rapid cellular 
turnover and is a non specific marker. 
• Recently NDGF Receptor expression and TRK –A gene 
expression have been proven to be associated with 
maturation of Neuroblastoma cells.They,thus play a role 
in disease regression in 4 S NB and indicate a good 
prognosis. 
 
Mass Screening for 4 S Neuroblastomas 
 
This was introduced in Japan 20years ago, to identify 
tumors at early stage and to treat them aggressively . They 
consists of mass screening of all infants at 6 months of age for 
Urine VMA levels through kits supplied to parents.This is then 
supplemented with Urine HVA / DA at 1 ½ years of age in certain 
studies to pick up cases missed in the initial screening .This 
screening programme increased the incidence of neuroblastomas 
detected many fold in this age group. However long term studies 
have shown that more than half of these tumors detected by 
 17
screening regress spontaneously .Thus the very purpose of early 
detection and aggressive treatment is affected. 
 
Studies have shown that tumors presenting at < 6 months of 
age are of favourable prognosis.Same holds good for cases 
detected by screening. Moreover it is the biological characteristics 
of the tumor which determine the final outcome. Thus even if 
tumors are detected by screening the biological prognostic factors 
should be studied. 
  
Aggressive treatment should be started only for those in the high 
risk category. 
 
Disease pattern : 
Excepting for the 1 to 2 % of cases which progress on to 
stage 4 rest of the 4S Neuroblastomas regress spontaneously . 
This process of regresson however has been poorly understood.No 
factors causing regression have been identified till now.However it 
has been proven beyond doubt that regression occurs by 
Apoptosis,ie, programmed cell death.But what causes it and how 
is still under evaluation. 
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The other phenomenon of tumor maturation which is a 
process of differentiation of neuroblastoma cells is better 
understood.The presence of nerve derived growth factors in the 
presence of their receptors induces the cells to undergo 
differentiation.Thus the cells start differentiating first to the 
ganglioneuroblastoma and then on to the benign ganglioneuroma 
form.The NDGF receptors being carried by the Trk A genes. Tumor 
biology for these genes gives a fair idea of predicting which of 
these tumors will mature. 
 
Management Strategies: 
There has been considerable controversy over whether to 
treat 4 S neuroblastomas actively or not. Studies supporting as well 
as opposing active intervention have been published .the rationale 
for chemotherapy in these patients is to prevent the disease from 
progressing onto stage 4 and to induce tumor regression.This 
however is countered by the fact ,the main causes for morbidity 
and mortality in this group are the secondary effects of the tumor 
and chemotherapy related  complications rather than the disease 
itself. 
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Thus the only definitive indication for chemotherapy in these 
cases is life threatening complications like respiratory 
distress,coagulopathy etc.However based on molecular studies 
,the disease has been categorized into three groups for favour of 
devising treatment protocol. 
Based on the North American cancer study group the 
treatment protocol is as follows. 
• Low risk :   
Chemotherapy only for life or organ threatening 
complications that cannot be relieved by surgical 
excision.  
• Intermediate risk : 
24 weeks of chemotherapy,consisting of moderate 
doses of  cyclophosphamide , carboplatin, 
doxorubicin, etoposide. Radiotherapy to be given if 
residual disease present after chemotherapy. 
• High risk  
24 weeks of high doses of the same drugs with 
inclusion of ifosphamide and cysplatin.For residual 
disease surgical excision and / or radiotherapy 
followed by myeloablative CT /RT and stem cell 
transplant. 
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Future Consideratons : 
 
• To identify persons with a genetic predisposition to 
develop this disease.1p36 is one locus which has 
been studied.Further studies to confirm the presence 
of other loci and to identify the predisposing loci are 
on and should be of great value in the future. 
 
• The present mass screening programme at 6 months 
has not proven to be very effective as it detects > 50 
% of masses likely to regress.Thus a newly devised 
screening programme done at  later age (10 to 18 
months ) using other catecholamines as well will 
improve the efficiency of such screening. 
 
• Urine VMA ,serum ferritin etc as tumor markers are 
not as reliable and as specific as alpha FP and beta 
HCG for other tumors.The development of molecular 
markers like N myc Amplification,1 p deletion,TRK –A 
expression,however are highly specific but not easily 
available.Thus further studies to identify specific 
markers of signficant prognostic value are needed . 
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• Further studies into the mechanism of tumor 
regression and maturation might provide insights into 
the pathology and behaviour of the disease .This 
might in turn help in devising specific treatment 
strategies with biologically directed therapy to replace 
the current toxic regimens. 
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AIM 
 
• To study the natural course of  disease and its 
regression pattern in 4 S Neuroblastomas. 
 
• To study the role of Chemotherapy in 4S 
neuroblastomas. 
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MATERIALS & METHODS 
 
This is a combined prospective and  retrospective study 
done at  Department of Paediatric Surgey,ICH, spanning a four 
year period from 1st June 2001 to 30th May 2005.All case records of  
the 52 patients with neuroblastoma ,who presented within this 
period were taken up for he study.In this, we had ten cases of 
stage 4S Neuroblastoma .The youngest age of presentation was 2 
months.The oldest patient was 11 months. 
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Sex distribution was equal,comprising gof five male and five 
female.The mode of presentation varied widely,commonest being 
an abdominal mass. 
 
SEX DISTRIBUTION
55
Male
Female
 
 
 
INCLUSION CRITERIA 
1. Age < 1 yr 
2. Histological evidence either from primary or secondary. 
3. Imaging studies ( Xray /USG / CT Scan ) to prove presence 
of stage I ,II disease in Adrenals or sympathetic chain with 
secondary confined to liver and marrow ( < 10  % 
involvement ) and absence of disease elsewhere. 
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Urine 24 hr VMA positivity was a supportive evidence in all 
cases though it was not an absolute necessity to confirm stage 4S 
disease. 
 
The investigation protocol was as follows. Tissue diagnosis was 
made based on wide bore needle aspiration of bone marrow in 7 
cases,ultrasound guided Tru cut biopsy in two and open biopsy in 
one case.Chest Xray was taken in all cases with plan for CT chest 
if any doubtful lesion on skiagram.There however was no need of a 
CT Chest, in any of these cases. Ultrasonogram abdomen was 
done in all the cases to detect abdominal masses and for liver 
involvement.Ultrasongram of the lesion was done in cervical 
tumors. CT Abdomen was done in 4 cases during initial workup. 
Complete skeletal survey was done in all cases  at presentation 
with bone scan prescribed for doubtful lesions.24 hour urine VMA 
was done in all cases.  
 
In the observation group cases were followed up with bi 
weekly ultrasonograms of the lesion / abdomen  and urine VMA 
studies. Bone Marrow was repeated once, the VMA became 
negative.Tumor regression  and disappearance on ultrasonogram 
was confirmed by CT scan in all cases. Once tumor regressed the 
children were followed up with monthly ultrasonogram and 24 hour 
urine VMA. 
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The study group was divided into two.Group I ,which did not 
receive any chemotherapy and was kept on close followup.Group II 
which received chemotherapy. The indications for chemotherapy 
varied from random situations to specific indications. 
 
Chemotherapy protocol we follow is a three drug regimen of 
intravenous cisplatin (100mg /m2), vincristine ( 1.5 mg/m2), 
cyclophosphamide ( 1000mg/m2) for each cycle over 3 days in 
divided doses.This cycle is repeated at 3 weekly intervals for a total 
of 6 cycles. 
 
Case Studies : 
 
The 10 cases have been divided into two groups.Group I, 
which did not receive chemotherapy ( Cases I to V ),Group II which 
received chemotherapy ( Cases VI to X). 
 
Case I : 
2 months old female child presented with hepatomegaly, 
imaging revealed multiple nodules in the liver suggesting 
secondary deposits.No other mass detected in the abdomen.Urine 
VMA was  positive, Bone marrow aspiration was positive for 
 27
clusters of round cells with rosette formation.Primary site was not 
detectable. Child was observed. Complete regression was 
documented at eight months of age. 
  
Case II : 
Two months old male child with massive hepatomegaly and 
in respiratory distress. Ultasonogram and CT showed multiple 
lesions in the liver,suggestive of Hemangioendothelioma. 
Laparotomy and hepatic artery ligation was done  in view of the 
emergency situation for decompressing the liver .The diagnosis at 
this stage being hemangioendothelioma.But,biopsies taken form 
liver lesions showed neuroblastoma.  
 
Urine VMA was positive.Bone marrow aspiration was 
positive for neuroblastoma.Child improved symptomatically and 
was kept on observation.Here also,the primary was not 
detectable.The disease regressed completely at 9 months of age. 
 
Case III 
8  months old female with a neck swelling,biopsy showing 
neuroblastoma. Liver ,bone marrow and VMA were positive.child 
was observed. Disease regressed completely  at 1 year and 2 
months of age.  
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Case IV : 
7 months old male child with right adrenal mass on 
ultrasonogram.Bone marrow and VMA were positive.Child was 
kept on observation .Disease regressed at 12 months of age. 
 
Case V : 
4 months old female child with multiple skin 
nodules.Ultrasonogram showed a paravertebral mass.VMA and 
BMA were positive.During the observation period,new skin nodules 
appeared.hence chemotherapy was contemplated.However due to 
low platelet count ,chemotherapy was not given.Surprisingly,within 
a couple of weeks nodules started regressing and completely 
disappeared.Disease regression was documented at 13 months of 
age. 
 
Case VI: 
11 months old female with an abdominal mass, 
Ultrasonogram showed a left lumbar paravertebral mass.Bone 
marrow and VMA were positive. Chemotherapy given. BMA and 
VMA were negative by 1 month.Mass showed  gradual regression 
and total regression of mass,occurred at 1 year and 6 months of 
age. 
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Case VII: 
4 months  old female child ,presented with hepatomegaly 
Ultrasonogram revealed a right lumbar paravertebral mass. Bone 
marrow and VMA were positive. Chemotherapy was given. Bone 
marrow and VMA reverted to normal in two weeks. Mass did not 
show regression in early phase. Infact,there was an increase in 
size of mass by 10 % ,in the first 4 weeks followed by slow 
regression. But by 10 months, the mass totally disappeared. 
 
Case VIII : 
Two months old male child, presented  with an  abdominal 
mass. .Ultrasonogram and CT revealed bilateral Adrenal masses 
,each measuring 5 to 6 cms.Hepatomegaly present .BMA and VMA 
positive.Chemotherapy was given.BMA and VMA negative by 1 
month.Adrenal masses came down by 1 cm in the first two 
months.Complete tumor regression was  documented at 14 months 
of age. 
 
Case IX : 
8 months old male child ,presented with hepatomegaly and 
a right adrenal mass .VMA and BMA positive.New skin nodules 
started appearing. Chemotherapy was given.VMA became 
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negative by 1 month.BMA negative by two months.Mass showed 
no regression at 1 ½ years of age . With the mass  persisting 
,laparotomy and excision was done. Hisptopathology was 
Ganglioneuroma. 
 
Case X : 
3 months male child  with massive hepatomegaly and 
respiratory discomfort . Right adrenal tumor was detected by 
ultrasonogram. BMA and VMA were positive.Chemotherapy was 
started.,Bone marrow and VMA were negative by six weeks. Mass 
showed slow regression.Complete regression was documented at 
9.5 months of age. 
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GROUP I 
Summary of Cases which were observed  without any active 
treatment. 
 
 Case I Case II Case III Case IV CaseV 
Age 
 
2mths 2mths 8 mths 7 mths 4 mths 
Primary 
 
Undetected Undetected Cevical Adrenal Lumbar 
Secondary 
 
Liver, BM Liver, BM Liver,BM Liver,BM Liver,BM,Skin
VMA 
 
+ ve +ve +ve +ve +ve 
Treatment 
Plan 
Observation Observaion Observation Observation Obser 
Regression 
 
9 months 9 months 14 months 12 months 13 months 
Maturation 
 
-- -- -- -- -- 
Follow Up  
    (age) 
1 year  2 years 1 year Lost Lost 
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GROUP II 
Summary of Cases which received Chemotherapy. 
 
 
 Case VI Case VII Case VIII Case IX CaseX 
Age 
 
11mths 4mths 2mths 8 mths 3 mths 
Primary 
 
Lumbar Lumbar Bil.Adrenal Adrenal Adrenal 
Secondary 
 
 BM BM,Liver BM,Liver BM,Liver,Skin Liver,BM 
VMA 
 
+ ve +ve +ve +ve +ve 
Treatment 
Plan 
Chemo Chemo Chemo Chemo Chemo 
Regression 
 
1 ½ yrs 10 months 14months -- 9.5 months 
Maturation 
 
-- -- -- At 1 ½ yrs -- 
Follow Up  
    (age) 
2 ½ yrs Lost 1 year Lost 1 ½ yrs 
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RESULTS 
 
Over the past 4 years we have had 52 cases of 
neuroblastomas.18 have been less than 1 year at presentation. 
Out of these 10 fit into the 4 SNB though some were not classified 
so at their first presentation. Six out of these cases presented less 
than 6 months of age. This forms a special subset as we will see in 
the discussion to follow. Male : Female ratio was 1:1 
 
 
 
4S DISTRIBUTION
10
42
4S NB
Other NB
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Group I : 
There were few unique presentations as in Case II which 
presented with massive hepatomegaly with respiratory distress. 
Imaging studies showed multiple hypoechoeic well circumcised 
lesions suggestive of a hemangioendothelioma.in view of the 
worsening distress caused by massive liver,hepatic artery ligation 
was performed as an emergency procedure.the biopsies taken 
from liver lesions showed Rosettes confirming a Neuroblastoma.No 
primary was detectable.urine VMA +ve.The child was observed 
,liver regressed lesions disappeared and VMA also became 
negative. 
 
In case V, skin nodules were the presenting complaint and 
turned out to be a 4SNB.During followup new skin nodules 
appeared.Just when CT was contemplated ,the nodules started 
regressing and CT was deferred.Complete tumor regression ws 
documented at 9 months of age. 
 
Case I, Case III and Case IV  were classical 4S presentation  
with complete tumor regression. 
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Group II ( Chemotherapy group ) 
These patients were chosen for chemotherapy,both randomly 
and based on a few indications.In case  VI, the age was > 10 
months at presentation.This was considered as borderline age 
group.The benefit of doubt given to patients and chemo given. 
 
Case VIII had Bilateral Adrenal tumor and was considered as 
poor risk group. Liver showed nodules on USG.BMA was +and 
VMA was also +.This was considered as Stage 4 disease at the 
outset and chemotherapy started. Extensive  search of  literature 
did not provide information about which group they could be 
included and how to stage them.The Bilateral  tumors as like all 
4SNeuroblastomas started showing regression and completely 
regressed at 1 yr of age.So we have reclassified them as 4S 
Neuroblastomas.  
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DISCUSSION 
 
Of the total of 52 cases ,10 are 4 SNeuroblastomas.which 
constitutes  18.%. Of the 10 cases, 6 presented under 6 months of 
age. This forms favourable prognostic group within 4 S 
Neuroblastomas.Studies have shown 1 to  2 %of 4 
SNeuroblastomas progress to stage 4 disease.UKCC group 1999  
study shows this disease progression rate to be < 0.5 % in the 
under 6 months group.It is 3 to 4% in the over 6 months group.This 
is of great statistical significance,as it implies a two to three fold 
increase in disease progression  rate . 
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Next is the under 3 months age group. Four out of the  10 
presented at or less than 3 months of age and all of them did very 
well with complete disease regression,documented within 1 year of 
age in all except one. Review of literature shows this is a bad 
prognostic group as they tolerate  the effects of diease 
poorly.particular problems being hepatomegaly causing respiratory 
compromise and coagulopathy.  
 
Other complications caused by the enlarging live are renal 
failure, bowel ischemia,vomiting and  aspiraton ,all caused by 
pressure effects over surrounding organs.In our series all 4 had 
massive hepatomegaly with respiratory distress in two of them.One 
of the cases,liver had HA ligation,the initial diagnosis being 
hemangioendothelioma.However all of them progressed well with  
good supportive  treatment. 
 
Case 8 is a very special one as it presented with bilateral 
adrenal masses with the disease spread pattern fitting into 4 S 
criteria.extensive search of literature did not reveal information 
about classifying such tumors.So,they were treated as stage 4 
disease with chemotherapy.However they showed remarkable 
tumor and disease regression similar to that of 4S neuroblastoma. 
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Moreover the disease pattern suggested that chemotherapy had no 
great role  in the disease regression.Thus the bilaterality of disease 
does not seem to affect staging as far as 4 SNB is concerned. 
 
There are two concepts in 4 S Neuroblastomas as far as 
disease pattern is concerned and activity is concerned—tumor 
regression,tumor maturation.Both signify regression of disease 
activity and form the basis of the natural history of stage 4 S 
neuroblastomas. 
 
Tumor Regression : 
Tumor regression is defined as complete cessation of 
disease activity ie both primary,secondaries and their effects.This 
includes complete disappearance of the primary  mass as well as 
manifest secondary disease,Next is reverting back of histology to 
normal.VMA also becomes negative.The disappearnce of mass 
lesions either the pimary or Liver lesions has to be documented by 
CT scan.Similarly histological and Biochemical markers negativity 
have to be proven by appropriate biopsies and 24 hour urine VMA 
tests.Various studies done during regressing phase in such tumors 
has shown APOPTOSIS to be the central event in tumor 
regression. 
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“Apoptosis” is described as programmed cell death.It is 
otherwise known as “cell suicide”, since it apparently involves 
active metablim by the dying cell. The sequence of leading to 
apoptosis is still unclear.But,it is currently thought that the process 
requires activation of an endogeneous endonucleus, perhaps via 
increases in cytosolic calcium, which results in fragmentation of 
DNA and subsequent cellular changes.  
 
Though apoptosis is a physiological event ,it can also be 
triggered by pathological stimuli,such as irradiation  and viruses. It 
is based on this knowledge that studies are on to investigate 
triggering factors of apoptosis which,in turn will lead on to disease 
regression.  
 
Apoptosis is characterized histologically by chromatin 
condensation,cytoplasmic blebbing and electrophoretically by DNA 
fragmentation.Of these,the DNA fragmentation is considered most 
representative and also easy to observe.On the electrophoretic 
chart,this is shown by multiple horizontal bands at various levels, 
looking like a ladder. This ladder pattern of DNA fragmentation,is 
taken as gold standard for apoptosis. 
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Another means of establishing apoptosis is by analyzing the 
proliferative activity of tumor cells.This can be done by 
immunostaining of specific protein marker—PCNA ( Proliferative 
cell Nuclear antigen) 
 
Anitbodies directed against PCNA have shown a marked 
decrease in the number of actively proliferating  cells among the 
tumor cells. 
 
Histological proof from regressing tumors  show tumor cells 
in various stages of apoptosis . However  the factors which induce 
these changes have not been identified.And  for the same reason  
the predictability of disease progression or regression becomes a 
problem.No definitive events or factors have been proven to predict 
the disease pattern in these patients. 
 
Though apoptosis was documented in two of our cases,we 
have depended predominantly upon imaging and routine HPE 
negativity  for establishing tumor and disease regression. 
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Tumor Maturation 
 
Tumor maturation is defined as progression of the tumor 
cells from less differentiated to better differentiated forms.In other 
words,from a malignant histology to a benign histology.Thus the 
histological forms identified are from intermediate 
ganglioneuroblastoma to a benign ganglioneurom 
 
In one of our cases despite chemotherapy the mass 
persisted  for > 8 months in almost same size. On Laparotomy and 
excision biopsy we found the histopathology to be ganglioneuroma. 
This tumor maturation has been attributed to many specific factors 
which are expressed by the Neuroblastoma cells. The most 
important of them being NDGF (Nerve Derived Growth Factor).  
 
The presence of these along with their receptors has been 
proven to induce differentiation amongst the neuroblastoma cells. 
The expression of these factors depends upon the presence of  Trk 
gene. This gene is one of the favourable progrostic factors in NB. 
Thus it correlates well with this concept of tumor maturation. Thus 
it also serves as a predictor of disease regression in these patients.  
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In our study,we have had nine cases with documented 
disease regression and one with tumor maturation.The duration 
taken for disease regression form the time of presentation has 
varied from 5 months to 10 months. Overall the average duration 
for disease regression was 6.8 months.(27 weeks). In group I ,it 
was 6.5 months and in group II,it was 7.5 months.Thus the duration 
taken for disease regression in the chemotherapy group was 
slightly longer than in the no chemo group. 
  
 Out of all these cases,in six cases the pattern of disease 
has been stringently observed.Based on these observations,three 
phases of disease regression have been identified. 
 
Phase I  : Regression of Secondary disease . 
This was the earliest phase during which the skin nodules 
and liver metastasis disappeared.The bone marrow which was 
initially positive became negative.Urine VMA also became 
negative. 
 
Phase II :  Slow phase of Mass regression. 
During this phase there was slow regression of primary 
mass by 10 to 20 % . 
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Phase III : Rapid phase of Mass regression: 
During this phase the mass regressed rapidly and 
disappeared. 
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On an average the phase I in these six cases ,lasted 
about 10 % ( 2 to 3 weeks ) of the total duration of disease 
regression. (27 weeks). There ,however was significant difference 
in phase I duration amongst the two groups.In the Group I patients, 
Phase I  lasted for 3 to 4 weeks. Where as, in the Group II,it lasted 
for only two weeks before going into phase II.Thus chemo can be 
claimed to have shortened the phase I duration,though it did not 
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have any bearing in the total duration of disease regression. 
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 The phase II duration was 12.5 weeks in Group I and 18 
weeks in Group II.This being the longest phase of the three, 
reflects the increased duration,taken for disease regression in 
Group II patients.  
 
The duration of Phase III did not vary much among the two 
groups – 3 weeks in Group I and 2.5 weeks in Group II. 
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Another point for discussion is disease progression or 
appearance of new lesions.In our study we have had one case 
where the mass has been progressively enlarging after 
presentation .Review of literature shows any such changes in 
volume of disease does not have a great bearing in the under 6 
month age group.This is because any disease presenting less than 
6 months of age is expected to reach a nidus before entering the 
regression phase.It is for this reason this group falls into good 
prognosis group. 
 
Next comes the major decision of whether to actively 
manage these patients or not. The options are surgery and 
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chemotherapy.Various papers have been published on antenatal 
detection of NB’s.All  these have led to detection of more and more 
masses and their early intervention before they enter into their 
natural regression pattern. 
 
These studies with other comparative studies have shown, 
such early detection and intervention was over treatment.This is 
because,they,when allowed in their natural course were found to 
regress spontaneously.There however is a 1 to 2 % chance of 
these cases going into stage 4.This has to be weighed against the 
morbidity and complications of surgery and chemotherapy. 
 
Studies published so far have proven beyond doubt that 
surgery does not have any role in prevention of disease 
progression.Thus surgery does not have any role in the early 
stages of 4SNB atleast. 
 
The next option is chemotherapy.There have been varying 
reports for and against chemotherapy in these case.In our 
study,we have compared two groups,the chemotherapy group Vs 
the no chemotherapy group. 
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The indications for chemotherapy in our group were random 
selection in 3 cases ,borderline age group in one case and bilateral 
tumor in another case. 
 
The chemotherapy protocol was half dose PVC regimen,at 3 
weekly intervals for 6 weeks. The observations were ,the average 
period for phase I was two  weeks, the average phase II duration 
was 24 weeks and  Phase III duration was 3 to 4 weeks. One of the 
chemotherapy group went in for tumor maturation. 
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Overall,there were no significant changes observed in the 
pattern of disease regression between the two groups, excepting 
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the phase I duration. Thus in our study chemotherapy ,did not 
seem to induce tumor regression or maturation.Neither did it 
reduce the duration of disease . Thus,the role of chemotherapy is 
limited to specific clinical situations. 
 
In our setup where N-mycamplification and DNS studies are 
practically not possible,we have defined a clinical protocol.Any 4S   
NB presenting after 6 months of age with evidence of progression 
of disease or non regression of disease might need chemotherapy. 
Progression of  disease is defined as increase in size of primary or 
appearance of new lesions. Non regression of disease is defined 
as failure of progression from phase I to phase II in a time frame of 
two months. 
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CONCLUSION 
 
This study of 4S Neuroblastomas in our institution over past 
4 years establishes the following things. In our study all cases 
(100%) have shown either tumor maturation or tumor regression. 
The subgroup of < 3 months have done remarkably well in our 
study unlike other studies. The secondary effects which are the 
causes of morbidity and mortality in these cases have not been 
observed in our study group. 
 
Most importantly, a set disease pattern has been identified 
in the 4 S Neuroblastomas. Though the duration of disease 
regression varied with an average period of 6.8 months.All these 
cases followed a set pattern with three phases. Phase I of 
regression of secondary disease. Phase II of slow tumor regression 
and phase III of rapid tumor regression. 
 
With regard to the role of chemotherapy in these cases, our 
study concludes there is no role for chemotherapy in these cases 
as a routine. Chemotherapy does not seem to alter the duration of 
disease neither does it initiate the process of maturation or tumor 
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regression. In fact the duration of disease regression has been 
slightly higher in the chemotherapy group. 
 
Based on all these we formulate the following indications for 
chemotherapy in 4SNB. 
 
Age > 6 months as presentation with 
1) Disease progression in form of new lesions / enlarging 
masses. 
2) Failure of disease regression identified by the non 
progression from Phase I to Phase II. 
 
This six month age cut off has been proposed based on 
studies proving increased chances of disease progression,in cases 
presenting beyond this age. 
 
Apart from these, any secondary effects of disease,which is 
life threatening ( Eg, rapidly enlarging liver ),warrants 
chemotherapy,in any age group. 
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